{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:06:10Z","timestamp":1791090370946,"version":"4.1.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,5,15]]},"abstract":"<jats:p>Treatment of patients with human immunodeficiency virus (HIV) protease inhibitors such as ritonavir can result in increases in CD4+ T-cell counts that are independent of a reduction in HIV-1 viral load. This lack of correlation between the 2 has led to the identification of additional effects of ritonavir that potentially alter HIV disease pathogenesis. Our previous studies indicated that ritonavir directly affects immune cell activation, proliferation, and susceptibility to apoptosis. We show here that ritonavir inhibited the activation and proliferation of primary endothelial cells and decreased the production of tumor necrosis factor \u03b1 (TNF-\u03b1) interleukin 6 (IL-6), IL-8, and vascular endothelial growth factor, factors that all contribute to tumor neovascularization and to the development of Kaposi sarcoma (KS) lesions. Ritonavir also suppressed the expression of vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and E-selectin, which correlated with a functional decrease in leukocyte adhesion. Transcriptional activation of nuclear factor-\u03baB, as induced by the KS-promoting factor TNF-\u03b1, the HIV-1 Tat protein, or the human herpesvirus 8 protein ORF74, was inhibited by ritonavir. KS-derived cell lines underwent apoptosis in vitro after treatment with ritonavir at concentrations that are obtained in clinical therapy (3-15 \u03bcM). In a KS mouse xenotransplantation model, ritonavir inhibited tumor formation and progression by KS-derived cells. Taken together, these data suggest that ritonavir has antineoplastic effects that are independent from its ability to inhibit the HIV protease.<\/jats:p>","DOI":"10.1182\/blood.v99.10.3771","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:48:18Z","timestamp":1033508898000},"page":"3771-3779","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":116,"title":["Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma"],"prefix":"10.1182","volume":"99","author":[{"given":"Shibani","family":"Pati","sequence":"first","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen B.","family":"Pelser","sequence":"additional","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Dufraine","sequence":"additional","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Bryant","sequence":"additional","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Marvin S.","family":"Reitz","sequence":"additional","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank F.","family":"Weichold","sequence":"additional","affiliation":[{"name":"From the Institute of Human Virology, University of Maryland Biotechnology Institute; Department of Microbiology and Immunology, University of Maryland; and Department of Biology, Morgan State University, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218213339800_B1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.","volume":"334","author":"Collier","year":"1996","journal-title":"N Engl J Med."},{"key":"2020021218213339800_B2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/978-1-4757-9209-6_33","article-title":"Efficacy of combination antiretroviral therapy.","volume":"394","author":"Collier","year":"1996","journal-title":"Adv Exp Med Biol."},{"key":"2020021218213339800_B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0166-3542(95)00928-0","article-title":"Combination therapy with zidovudine, didanosine and saquinavir.","volume":"29","author":"Collier","year":"1996","journal-title":"Antiviral Res."},{"key":"2020021218213339800_B4","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1056\/NEJM199512073332204","article-title":"A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.","volume":"333","author":"Markowitz","year":"1995","journal-title":"N Engl J Med."},{"key":"2020021218213339800_B5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1056\/NEJM199804093381517","article-title":"Improvement in CD4+ cell counts despite persistently detectable HIV load.","volume":"338","author":"Levitz","year":"1998","journal-title":"N Engl J Med."},{"key":"2020021218213339800_B6","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.280.5371.1871","article-title":"HIV treatment failure: testing for HIV resistance in clinical practice.","volume":"280","author":"Perrin","year":"1998","journal-title":"Science."},{"key":"2020021218213339800_B7","first-page":"2568","article-title":"HIV-1 protease inhibitor modulates activation of peripheral blood derived CD4+ T-cells and decreases their susceptibility to apoptosis in vitro [abstract].","volume":"90","author":"Sloand","year":"1997","journal-title":"Blood."},{"key":"2020021218213339800_B8","first-page":"261","article-title":"HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells.","volume":"2","author":"Weichold","year":"1999","journal-title":"J Hum Virol."},{"key":"2020021218213339800_B9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V94.3.1021.415k29_1021_1027","article-title":"Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo.","volume":"94","author":"Sloand","year":"1999","journal-title":"Blood."},{"key":"2020021218213339800_B10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B11","doi-asserted-by":"crossref","first-page":"35734","DOI":"10.1074\/jbc.274.50.35734","article-title":"How an inhibitor of the HIV-I protease modulates proteasome activity.","volume":"274","author":"Schmidtke","year":"1999","journal-title":"J Biol Chem."},{"key":"2020021218213339800_B12","doi-asserted-by":"crossref","first-page":"13120","DOI":"10.1073\/pnas.95.22.13120","article-title":"An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.","volume":"95","author":"Andre","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.1997.03540260059037","article-title":"HIV-1 protease inhibitors. A review for clinicians.","volume":"277","author":"Deeks","year":"1997","journal-title":"JAMA."},{"key":"2020021218213339800_B14","first-page":"145","article-title":"HIV-1 protease inhibitors.","volume":"98","author":"Deeks","year":"1997","journal-title":"AIDS Clin Rev."},{"key":"2020021218213339800_B15","first-page":"236","article-title":"Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy.","volume":"34","author":"Diz","year":"1998","journal-title":"Oral Oncol."},{"key":"2020021218213339800_B16","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS."},{"key":"2020021218213339800_B17","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJM199512073332303","article-title":"A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.","volume":"333","author":"Danner","year":"1995","journal-title":"N Engl J Med."},{"key":"2020021218213339800_B18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0190-9622(97)70188-9","article-title":"Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy.","volume":"37","author":"Burdick","year":"1997","journal-title":"J Am Acad Dermatol."},{"key":"2020021218213339800_B19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-103-5-744","article-title":"The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome.","volume":"103","author":"Safai","year":"1985","journal-title":"Ann Intern Med."},{"key":"2020021218213339800_B20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.2643161","article-title":"AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects.","volume":"243","author":"Ensoli","year":"1989","journal-title":"Science."},{"key":"2020021218213339800_B21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0960-9822(95)00093-5","article-title":"AIDS. Viruses, cytokines and Kaposi's sarcoma.","volume":"5","author":"Ganem","year":"1995","journal-title":"Curr Biol."},{"key":"2020021218213339800_B22","first-page":"329","article-title":"Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity.","volume":"78","author":"Hober","year":"1989","journal-title":"Clin Exp Immunol."},{"key":"2020021218213339800_B23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-9343(89)90367-7","article-title":"Cytokines and acquired immunodeficiency syndrome [letter].","volume":"86","author":"Fuchs","year":"1989","journal-title":"Am J Med."},{"key":"2020021218213339800_B24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1172\/JCI114678","article-title":"Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.","volume":"86","author":"Emilie","year":"1990","journal-title":"J Clin Invest."},{"key":"2020021218213339800_B25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1098\/rstb.2000.0778","article-title":"Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.","volume":"356","author":"Boshoff","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"2020021218213339800_B26","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI117849","article-title":"Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells.","volume":"95","author":"Fiorelli","year":"1995","journal-title":"J Clin Invest."},{"key":"2020021218213339800_B27","first-page":"273","article-title":"Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: implications in pathogenesis.","volume":"1","author":"Galea","year":"1998","journal-title":"J Hum Virol."},{"key":"2020021218213339800_B28","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS- associated Kaposi's sarcoma.","volume":"266","author":"Chang","year":"1994","journal-title":"Science."},{"key":"2020021218213339800_B29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/91.17.1453","article-title":"Perspective on Kaposi's sarcoma: facts, concepts, and conjectures.","volume":"91","author":"Reitz","year":"1999","journal-title":"J Natl Cancer Inst."},{"key":"2020021218213339800_B30","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1073\/pnas.92.11.4838","article-title":"Angiogenic properties of human immunodeficiency virus type 1 Tat protein.","volume":"92","author":"Albini","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B31","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1128\/JVI.66.12.7159-7167.1992","article-title":"Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines.","volume":"66","author":"Buonaguro","year":"1992","journal-title":"J Virol."},{"key":"2020021218213339800_B32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)81318-5","article-title":"NF-kappa B: ten years after.","volume":"87","author":"Baeuerle","year":"1996","journal-title":"Cell."},{"key":"2020021218213339800_B33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(08)60742-7","article-title":"NF-kappa B as a frequent target for immunosuppressive and anti- inflammatory molecules.","volume":"65","author":"Baeuerle","year":"1997","journal-title":"Adv Immunol."},{"key":"2020021218213339800_B34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-kappa B and I kappa B proteins: new discoveries and insights.","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annu Rev Immunol."},{"key":"2020021218213339800_B35","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.V98.4.1078","article-title":"Antiapoptotic mechanism of HIV protease inhibitor: preventing mitochondrial transmembrane potential loss.","volume":"98","author":"Phenix","year":"2001","journal-title":"Blood."},{"key":"2020021218213339800_B36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00002030-199706000-00003","article-title":"The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line.","volume":"11","author":"Albini","year":"1997","journal-title":"AIDS."},{"key":"2020021218213339800_B37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0092-8674(00)80430-4","article-title":"Caspases: intracellular signaling by proteolysis.","volume":"91","author":"Salvesen","year":"1997","journal-title":"Cell."},{"key":"2020021218213339800_B38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.94.3.855","article-title":"Activation of the cell death program by inhibition of proteasome function.","volume":"94","author":"Drexler","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1096\/fasebj.9.10.7542214","article-title":"Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers.","volume":"9","author":"Collins","year":"1995","journal-title":"FASEB J."},{"key":"2020021218213339800_B40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0022-1759(94)90391-3","article-title":"An adhesion assay using minimal shear force to remove nonadherent cells.","volume":"170","author":"St John","year":"1994","journal-title":"J Immunol Methods."},{"key":"2020021218213339800_B41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/34193","article-title":"G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator [see comments] [published erratum appears in Nature. 1998;392:210].","volume":"391","author":"Bais","year":"1998","journal-title":"Nature."},{"key":"2020021218213339800_B42","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.4049\/jimmunol.149.11.3727","article-title":"Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis.","volume":"149","author":"Barillari","year":"1992","journal-title":"J Immunol."},{"key":"2020021218213339800_B43","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/JVI.67.1.277-287.1993","article-title":"Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.","volume":"67","author":"Ensoli","year":"1993","journal-title":"J Virol."},{"key":"2020021218213339800_B44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/345084a0","article-title":"Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.","volume":"345","author":"Ensoli","year":"1990","journal-title":"Nature."},{"key":"2020021218213339800_B45","doi-asserted-by":"crossref","first-page":"8660","DOI":"10.1128\/JVI.75.18.8660-8673.2001","article-title":"Activation of NF\u03baB by the HHV-8 chemokine receptor ORF74: evidence for a paracrine model of KS pathogenesis.","volume":"75","author":"Pati","year":"2001","journal-title":"J Virol."},{"key":"2020021218213339800_B46"},{"key":"2020021218213339800_B47","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.282.5395.1837","article-title":"The enigmas of Kaposi's sarcoma.","volume":"282","author":"Gallo","year":"1998","journal-title":"Science."},{"key":"2020021218213339800_B48","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1074\/jbc.271.2.736","article-title":"Interleukin 6 induces the expression of vascular endothelial growth factor.","volume":"271","author":"Cohen","year":"1996","journal-title":"J Biol Chem."},{"key":"2020021218213339800_B49","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1073\/pnas.87.8.3092","article-title":"Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.","volume":"87","author":"Motro","year":"1990","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1600-065X.1992.tb01412.x","article-title":"Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma.","volume":"127","author":"Ensoli","year":"1992","journal-title":"Immunol Rev."},{"key":"2020021218213339800_B51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/1074-7613(95)90030-6","article-title":"The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression.","volume":"2","author":"Read","year":"1995","journal-title":"Immunity."},{"key":"2020021218213339800_B52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(92)90123-T","article-title":"Induction of apoptosis in fibroblasts by c-myc protein.","volume":"69","author":"Evan","year":"1992","journal-title":"Cell."},{"key":"2020021218213339800_B53","first-page":"1915","article-title":"Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis.","volume":"6","author":"Askew","year":"1991","journal-title":"Oncogene."},{"key":"2020021218213339800_B54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1126\/science.274.5288.784","article-title":"TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB [see comments].","volume":"274","author":"Wang","year":"1996","journal-title":"Science."},{"key":"2020021218213339800_B55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.","volume":"5","author":"Wang","year":"1999","journal-title":"Nat Med."},{"key":"2020021218213339800_B56","first-page":"437","article-title":"Immunopathogenesis of Kaposi's sarcoma.","volume-title":"Immunology of HIV Infection.","author":"Samaniego","year":"1997"},{"key":"2020021218213339800_B57","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1128\/JVI.73.8.7080-7086.1999","article-title":"Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.","volume":"73","author":"Demarchi","year":"1999","journal-title":"J Virol."},{"key":"2020021218213339800_B58","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.4049\/jimmunol.164.10.5156","article-title":"Differential requirement for p56lck in HIV-tat versus TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal kinase, and apoptosis.","volume":"164","author":"Manna","year":"2000","journal-title":"J Immunol."},{"key":"2020021218213339800_B59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.191.3.417","article-title":"Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? [comment].","volume":"191","author":"Cesarman","year":"2000","journal-title":"J Exp Med."},{"key":"2020021218213339800_B60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0192-0561(94)90026-4","article-title":"Cytokines in HIV infection.","volume":"16","author":"Emilie","year":"1994","journal-title":"Int J Immunopharmacol."},{"key":"2020021218213339800_B61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/scbi.1997.0061","article-title":"Rel\/NF-kappa B and I kappa B factors in oncogenesis.","volume":"8","author":"Luque","year":"1997","journal-title":"Semin Cancer Biol."},{"key":"2020021218213339800_B62","first-page":"1367","article-title":"Rel\/NF-kappaB\/IkappaB proteins and cancer.","volume":"13","author":"Gilmore","year":"1996","journal-title":"Oncogene."},{"key":"2020021218213339800_B63","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/sj.onc.1203221","article-title":"Aberrant rel\/nfkb genes and activity in human cancer.","volume":"18","author":"Rayet","year":"1999","journal-title":"Oncogene."},{"key":"2020021218213339800_B64","first-page":"M55","article-title":"The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance.","volume":"1470","author":"Mayo","year":"2000","journal-title":"Biochim Biophys Acta."},{"key":"2020021218213339800_B65","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.070047997","article-title":"Bax degradation by the ubiquitin\/proteasome-dependent pathway: involvement in tumor survival and progression.","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218213339800_B66","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.","volume":"269","author":"Pagano","year":"1995","journal-title":"Science."},{"key":"2020021218213339800_B67","first-page":"2649","article-title":"In vivo ubiquitination and proteasome-mediated degradation of p53(1).","volume":"56","author":"Maki","year":"1996","journal-title":"Cancer Res."},{"key":"2020021218213339800_B68","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.4049\/jimmunol.166.5.3130","article-title":"Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells.","volume":"166","author":"Marshansky","year":"2001","journal-title":"J Immunol."},{"key":"2020021218213339800_B69","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/sj.onc.1202686","article-title":"Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.","volume":"18","author":"Rousseau","year":"1999","journal-title":"Oncogene."},{"key":"2020021218213339800_B70","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell."},{"key":"2020021218213339800_B71","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents.","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"2020021218213339800_B72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment.","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs."},{"key":"2020021218213339800_B73","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/1097-0142(20000901)89:5<995::AID-CNCR8>3.0.CO;2-8","article-title":"Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma.","volume":"89","author":"Hackel","year":"2000","journal-title":"Cancer."},{"key":"2020021218213339800_B74","first-page":"613","article-title":"Proteases as prognostic markers in cancer.","volume":"2","author":"Duffy","year":"1996","journal-title":"Clin Cancer Res."},{"key":"2020021218213339800_B75","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V98.2.383","article-title":"The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals.","volume":"98","author":"Chavan","year":"2001","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/10\/3771\/1685081\/h81002003771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/10\/3771\/1685081\/h81002003771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T05:35:19Z","timestamp":1704605719000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/10\/3771\/107045\/Antitumorigenic-effects-of-HIV-protease-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,15]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.10.3771","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5,15]]}}}